A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.

开始日期2025-06-01

申办/合作机构

齐鲁制药有限公司

CTR20244889

/ Active, not recruitingN/A

评估受试制剂阿巴帕肽注射液与参比制剂阿巴帕肽注射液（Tymlos®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究

主要研究目的研究空腹状态下皮下注射受试制剂阿巴帕肽注射液与参比制剂阿巴帕肽注射液（Tymlos®）在健康成年受试者体内的药代动力学，评价空腹状态下皮下注射两种制剂的生物等效性。次要研究目的研究受试制剂阿巴帕肽注射液在健康受试者中的安全性。

开始日期2025-01-02

申办/合作机构

齐鲁制药有限公司

NCT04626141

/ Withdrawn临床4期

Time to Healing, Loss of Fixation, and Loss of Alignment in Supracondylar Distal Femur Fractures Among a Geriatric Population Treated With Abaloparatide: A Double-Blind Placebo Controlled Study

Supracondylar femur fractures in the geriatric population present a unique challenge to the orthopaedic surgeon both in terms of fixation, healing, and final extremity axial alignment. Pulsed dosing of parathyroid hormone derivatives (Forteo) has been shown to increase bone mass, and several studies in Europe have demonstrated its benefit as an adjuvant for fracture healing. Abaloparatide represents a new compound which similarly offers great potential for accelerating fracture healing, especially healing associated with callous formation. This is a randomized, double blind placebo-controlled trial to compare a group of patients being treated for supracondylar distal femur fractures who receive abaloparatide (n=38) with a control group of patients who receive a placebo (n=38).

开始日期2024-06-01

申办/合作机构

Geisinger Ventures

[+1]

100 项与阿巴帕肽相关的临床结果

登录后查看更多信息

100 项与阿巴帕肽相关的转化医学

登录后查看更多信息

100 项与阿巴帕肽相关的专利（医药）

登录后查看更多信息

351

项与阿巴帕肽相关的文献（医药）

2025-03-15·JOURNAL OF BONE AND MINERAL RESEARCH

Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study

Article

作者: Brown, Jacques P ; Binkley, Neil ; Wang, Yamei ; Eastell, Richard ; Adler, Robert A ; Kendler, David ; Lewiecki, E Michael ; Orwoll, Eric S ; Mitlak, Bruce H

Abstract:

Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-mo BMD increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men. In this analysis, the correlation between changes from baseline in fasting intact serum procollagen type I N propeptide (PINP) and serum CTX at 1, 3, 6, and 12 mo and percent increase from baseline in BMD at 12 mo in men from the randomized phase 3 ATOM study (NCT03512262) were evaluated using Pearson’s correlation coefficients. The uncoupling index (UI), a measure of the balance between markers of bone formation (PINP) and bone resorption (CTX), with positive UI favoring bone formation, was calculated. Results in men were compared to 12-mo results for women from the ACTIVE study using the z score test after Fisher’s Z transformation. In abaloparatide-treated men, PINP increases at 1 mo (r = 0.485), 3 mo (r = 0.614), 6 mo (r = 0.632), and 12 mo (r = 0.521) were highly correlated (p < .0001) with 12-mo LS BMD increases. The mean UI for abaloparatide-treated men was greater than placebo as early as 1 mo (2.26 vs −0.25). At month 3, the mean UI for men was greater (1.32) than for women (0.88) (p < .001). There was a significant correlation between 3-mo UI and LS BMD at 12 mo in both men (r = 0.453; p < .001) and women (r = 0.252; p < .01). UI at months 6 and 12 were also significantly correlated with 12-mo LS BMD in men and women, but the correlation was stronger in men than women. These data support that early changes in BTMs in men treated with abaloparatide are associated with subsequent changes in BMD similar to what has been reported in women.

2025-02-18·The Journal of clinical endocrinology and metabolism

Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study

Article

作者: Stokar, Joshua ; Szalat, Auryan

Abstract:

Context:

Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent antiosteoporotic agent with osteoanabolic properties. Clinical use of romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following the pivotal ARCH trial.

Objective:

This work aimed to assess real-world CV safety of romosozumab vs alternative osteoanabolic therapies used for treatment of severe osteoporosis.

Methods:

Data were obtained from TriNetX, a global federated health research network including real-time electronic medical records from 113 health care organizations with 136 460 930 patients across 16 countries at time of analysis. Inclusion criteria were age 40 years or older, a diagnosis of osteoporosis and prescription of romosozumab or a parathyroid hormone (PTH) analogue (teriparatide/abaloparatide) during August 2019 through August 2022. Propensity-score-matched cohorts were created 1:1 using demographic variables, comorbidities, and medications. Kaplan-Meier analysis was used to estimate the probability of the outcomes. Outcome measures included incident 3-point major adverse CV event or death (3P-MACE) during 1-year of follow-up after the initial prescription.

Results:

A total of 5626 and 15 986 patients met the criteria for romosozumab and PTH analogue cohorts, respectively, with 5610 patients per group following propensity score matching. 3P-MACE was significantly less frequent in the romosozumab vs PTH analogue cohort (158 vs 211 patients with an outcome; P = .003) with reductions in the individual components of the composite outcome: myocardial ischemic events (31 vs 58; P = .003); cerebrovascular events 56 vs 79; P = .037; deaths (83 vs 104; P = .099).

Conclusion:

In a diverse, real-world setting, prescription of romosozumab for osteoporosis is associated with fewer adverse CV events when compared to PTH analogue therapy.

2025-02-01·Endocrine Practice

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis

Article

作者: Mitlak, Bruce H ; Rizzoli, René ; Reginster, Jean-Yves ; Wang, Yamei ; Chiodo, Joseph ; Curtis, Jeffrey R ; Mitlak, Bruce H. ; Cortet, Bernard ; DeSapri, Kristi T ; LaBaume, Clayton T. ; Tabatabai, Laila ; LaBaume, Clayton T ; Curtis, Jeffrey R. ; DeSapri, Kristi T. ; Cosman, Felicia

BACKGROUND:

Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture. In the Abaloparatide Comparator Trial In Vertebral Endpoints study, bone mineral density improvements were significantly greater with abaloparatide compared to teriparatide at the total hip and femoral neck. We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.

METHODS:

This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide. The index date was the date of the initial prescription dispensed. Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score-matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.

RESULTS:

Patients (21 676 per cohort) were well matched on 73 baseline parameters. Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months. Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; P = .027); 947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; P = .003). There were no significant treatment-subgroup interactions (P ≥ .2). Cardiovascular events were similar between groups.

CONCLUSIONS:

There were significantly lower rates of hip and nonvertebral fractures with abaloparatide compared to teriparatide, which were consistent across subgroups. No differences in cardiovascular safety were noted between cohorts.

项与阿巴帕肽相关的新闻（医药）

2025-03-28

·九洲药业

【速递】阿斯利康：PTHR1激动剂治疗甲状旁腺功能减退症达3期主要终点

●试验按计划持续至52周，以进一步确定风险获益状况。Jiuzhou News CALYPSO III期试验的高级结果表明，与安慰剂相比，在研甲状旁腺激素（PTH）受体1激动剂eneboparatide (AZP-3601）在24周时对患有慢性甲状旁腺功能减退症（HypoPT）的成年人达到了其主要终点，且具有统计学意义。主要终点是白蛋白调整血清钙水平恢复正常以及不再依赖活性维生素D和口服钙疗法的综合结果。阿斯利康罕见病业务Alexion首席执行官Marc Dunoyer表示：“患有HypoPT（一种罕见内分泌疾病）的人患高钙尿症、骨质减少和骨质疏松症的风险通常较高，而CALYPSO试验的结果强调了eneboparatide有可能成为这些患者的另一种选择。我们期待在52周时审查临床结果，以全面描述风险获益情况。”Eneboparatide耐受性良好。在24周随机治疗期后，所有患者在持续的长期延长期内接受eneboparatide治疗，直至52周。完整的疗效和安全性数据将在52周时进行分析。Alexion计划与全球卫生当局分享这些数据，并在即将召开的医学会议上展示它们。甲状旁腺功能减退症（HypoPT） HypoPT是一种罕见的内分泌疾病，由甲状旁腺激素（PTH）缺乏引起，其特征是血液中钙降低和磷酸盐水平升高。甲状旁腺激素（PTH）生理作用的失调可导致临床表现，包括对肾脏和骨骼的负面影响。HypoPT是已知的最大罕见疾病之一，影响美国和欧盟超过200,000人，其中约80%为女性。大约75%的甲状旁腺功能减退症患者的主要原因是颈部手术中甲状旁腺受伤或被切除。尽管有可用的治疗方法，但甲状旁腺功能减退症患者仍然面临巨大的未满足需求。CALYPSO试验 CALYPSO是一项全球性III期随机、双盲、安慰剂对照、多中心试验，旨在评估eneboparatide对慢性甲状旁腺功能减退症成人患者的疗效和安全性。共有202名接受标准治疗（活性维生素D和口服钙补充剂）的患者按2:1的比例随机接受eneboparatide或安慰剂治疗。主要疗效终点是治疗24周后，达到白蛋白调整血清钙水平正常范围且不再依赖标准治疗的患者比例的综合结果。关键次要疗效终点包括基线高钙尿症患者24 小时尿钙水平恢复正常，以及评估患者报告的反映身体症状和生活质量影响的结果。Eneboparatide (AZP-3601) Eneboparatide (AZP-3601）是一种研究性甲状腺旁素（PTH）受体1激动剂，用于治疗慢性甲状旁腺功能减退症（HypoPT）。它旨在与PTH受体1的特定构象以高亲和力结合，以恢复PTH功能，从而控制HypoPT的症状，同时保持肾功能和骨骼健康。Eneboparatide已被美国食品药品管理局授予快速通道资格和孤儿药资格，并被欧洲药品管理局授予孤儿药资格，用于治疗HypoPT。小结据2022年第二届国际研讨会指南《甲状旁腺功能减退症的评估和管理》，甲状旁腺功能减退症除了具有典型的血钙低和磷酸盐升高的指征外，还有一些并发症，严重地影响着患者生活质量，如白内障、感染、肾钙化/肾结石、肾功能不全、癫痫、沮丧、缺血性心脏病和心律失常等。▲甲状旁腺功能减退症的并发症紊乱的钙调控导致PTH水平降低，影响着身体各个器官，大大增加了并发症的发生概率。目前临床上的常规治疗手段包括直接补钙（碳酸钙或柠檬酸钙）、间接补钙（活性维生素D来促进肠钙吸收和调节骨形成）以及限制钙排泄（噻嗪类利尿剂增加肾小管钙重吸收）。▲钙调控紊乱直到2024年美国FDA批准了Ascendis Pharma公司的palopegteriparatide，甲状旁腺功能减退症患者迎来了针对PTH减少这一病因的新型疗法。Teriparatide[1-34]是一种甲状腺旁素衍生物，最早在上个世纪用于治疗绝经后妇女具有高骨折风险的骨质疏松症，但由于它具有极短（1小时）的半衰期，无法产生足够的暴露量来维持体内活性，因而长期以来无法用来治疗甲状旁腺功能减退症。阿斯利康eneboparatide则通过修改M-PTH(1-30)/PTHrP多肽里的关键氨基酸，获得了活性更强的PTH衍生物。▲Eneboparatide的氨基酸序列天然的PTHrP[1-34] abaloparatide具有较弱的R0亲和力，而只有在R0状态下才会激活PTH1R的下游信号通路。▲Eneboparatide的设计机理阿斯利康的eneboparatide正是一种具有强力R0亲和力的PTH衍生物。▲Eneboparatide对R0具有高亲和力Eneboparatide能够持久地刺激下游cAMP信号的产生，并长时间维持血清钙水平。▲Eneboparatide的PD数据Eneboparatide哪怕半衰期与Teriparatide[1-34]相似，但它依旧能长时间地维持相应的药理学功能。▲Eneboparatide的PD数据Palopegteriparatide和eneboparatide是两种不同设计理念的药物，同样能够有效地用于治疗甲状旁腺功能减低症。除此之外，还有其他值得关注的目前临床在研的PTH衍生物。Entera Bio公司正在开发口服Teriparatide[1-34]，通过制剂配方的方式来实现，配方里有SNAC（增加多肽的渗透性，强化肠道吸收）和大豆胰蛋白酶抑制剂（减少多肽的胃肠道水解）。MBX Biosciences公司正在开发每周一次皮下注射的canvuparatide PTH[1-32]，也是一种前药的方式，通过脂肪酰化来结合体内的白蛋白，从而延长半衰期。还有信立泰的SAL056每周皮下注射一次的Teriparatide[1-34]，处于上市申请阶段，具体长效机理未披露。▲活跃的临床在研PTH衍生物▲活跃的临床在研PTH衍生物结构参考资料1.https://www.astrazeneca.com/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint.html2.https://onlinelibrary.wiley.com/doi/10.1002/jbmr.46913.https://www.nature.com/articles/nrdp2017554.https://amolytpharma.com/wp-content/uploads/2023/06/ECE-23-Ravel-et-al-AZP-3601-on-Bone-in-NHP-Final-5-8-23.pdf5.https://amolytpharma.com/wp-content/uploads/2024/07/12-ECE24-Culler-OC2.3-A-Translational-Approach-Final.pdf6.https://www.sciencedirect.com/science/article/pii/S2590156721000268?via%3Dihub7.https://mbxbio.com/our-science/#how-peps-work免责申明本公众号注明原创的内容权利均属九洲药业所有，未经授权，不得擅自使用或许可他人使用。如需获得授权，请和九洲药业提前联系。已获得授权的，应在授权范围内使用，并注明来源且不得再全部或部分转授权他人。本公众号对转载、分享的内容、陈述、观点判断保持中立，不对所包含内容的合法性、准确性、可靠性或完善性提供任何明示或暗示的保证，该等内容版权归原作者所有，仅供学习参考之用，若对转载、分享的内容有任何权利疑问，烦请联系九洲药业。

临床3期孤儿药临床结果快速通道临床成功

2025-01-02

·access wire

Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories

BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (\"Radius\" or the \"Company\"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.\"We are very pleased to enter into a partnership with Pharmanovia with the goal of making abaloparatide available to patients in additional global markets,\" said Scott Briggs, Chief Executive Officer of Radius. \"This collaboration partners two companies that share a commitment to improving the lives of patients with osteoporosis. With Pharmanovia\'s expertise in osteoporosis and their proven track record of success in these territories, we can look forward to significantly expanding abaloparatide access to patients in need of osteoporosis treatment options.\"\"We are thrilled to expand our portfolio and bring to the Asia Pacific region such an important and innovative osteoporosis treatment,\" said James Burt, Chief Executive Officer of Pharmanovia. \"This deal recognizes the strength of our commercial model in APAC, and China in particular, where we have one of the leading osteoporosis commercial platforms.\"Under the terms of the Licensing Agreement, Radius would be eligible to receive an upfront payment as well as regulatory and commercial milestones plus tiered royalties on net sales.About Radius:Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius\' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company\'s presence in bone health.About Pharmanovia:Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences. With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas - Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.Contacts:Al Medwar: Senior Vice President, Business and Corporate Development, Radius Email: [email protected]SOURCE: Radius Health Related Documents:

上市批准引进/卖出

2024-12-09

·access wire

Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia

BOSTON, MA / ACCESSWIRE / December 9, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Theramex the exclusive commercialization rights to ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, for Mexico, Canada, Israel, South Africa, and Russia. Theramex will also have the opportunity to commercialize ELADYNOS® in other agreed upon unpartnered regions. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.Under the License Agreement, Radius will receive an upfront and milestone payment plus tiered royalties."Theramex has been an excellent collaborative partner, and we are very pleased to expand our abaloparatide partnership to include additional important global markets," said Scott Briggs, Chief Executive Officer of Radius. "Radius is committed to making abaloparatide accessible to patients, and the expansion of our existing partnership helps provide access to additional patients in need of osteoporosis treatment options.""Following the launch of abaloparatide in Europe, we are excited to bring this innovative product to more patients globally and drive further growth through our direct markets and our commercial partnerships. This agreement expands our successful relationship with Radius, and we look forward to continuing our close collaboration," said Rob Stewart, Chief Executive Officer of Theramex.In addition to these new territories, Theramex will continue to commercialize and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia, and Brazil. ELADYNOS® received approval in the European Economic Area in December 2022 and Australia in November 2024 and has been launched in select countries.About Radius:Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health.About Theramex:Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering osteoporosis, contraception, fertility, menopause and uterine health. Theramex's commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex's vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.Contacts:Al Medwar: Senior Vice President, Business and Corporate Development, Radius Email: [email protected]Edward Rees: Chief Corporate Development Officer, TheramexEmail: to [email protected]SOURCE: Radius Health

上市批准引进/卖出

100 项与阿巴帕肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10885	阿巴帕肽	H05AA	DB05084

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
骨质疏松症	日本	Teijin Ltd.	2022-08-31
绝经期后骨质疏松	美国	Radius Health, Inc.	2017-04-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨质疏松性骨折	临床3期	美国	Radius Health, Inc.	2018-09-20
骨折	临床3期	美国	Radius Health, Inc.	2011-04-01
骨折	临床3期	阿根廷	Radius Health, Inc.	2011-04-01
骨折	临床3期	巴西	Radius Health, Inc.	2011-04-01
骨折	临床3期	捷克	Radius Health, Inc.	2011-04-01
骨折	临床3期	丹麦	Radius Health, Inc.	2011-04-01
骨折	临床3期	爱沙尼亚	Radius Health, Inc.	2011-04-01
骨折	临床3期	中国香港	Radius Health, Inc.	2011-04-01
骨折	临床3期	立陶宛	Radius Health, Inc.	2011-04-01
骨折	临床3期	波兰	Radius Health, Inc.	2011-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01343004 (ACTIVE, Pubmed \| Menopause)	临床3期	骨质疏松性骨折	-	Abaloparatide	艱鏇繭蓋廠餘觸憲壓襯(糧襯築艱願蓋範繭選鏇) = 8.9% 鹹衊遞窪簾遞遞艱窪膚 (鑰鑰餘窪網艱網網窪簾 ) 更多	积极	2025-02-25
				Placebo
NCT04760782 (CTgov)	临床2期	骨折	22	Hard collar immobilization+Abaloparatide (Treatment Group)	鏇糧餘餘顧鏇餘齋簾製(製衊網鹽齋餘壓觸膚蓋) = 鏇繭夢夢繭積鹹鬱襯憲網鹽簾壓襯鏇窪膚顧繭 (鬱遞範糧餘艱廠糧醖鹽, 艱艱淵壓鹹製壓憲範築 ~ 膚鹽願夢鏇鏇壓襯艱構) 更多	-	2024-09-19
				Hard collar immobilization (Historical Control Group)	鏇糧餘餘顧鏇餘齋簾製(製衊網鹽齋餘壓觸膚蓋) = 願夢鏇鏇膚觸觸鹽選衊網鹽簾壓襯鏇窪膚顧繭 (鬱遞範糧餘艱廠糧醖鹽, 顧艱顧積觸襯製襯衊遞 ~ 築憲網網範簾衊鑰餘醖) 更多
NCT03512262 (ATOM, ENDO2024)	临床3期	骨硬化 PINP \| CTX	228	Abaloparatide 80 µg	簾遞膚鬱獵鬱網衊簾鬱(鏇艱選壓淵憲憲蓋鹹積) = 網簾襯築鹽遞鏇鏇鬱觸蓋廠觸觸鹹齋遞壓積選 (網簾衊壓製醖壓窪觸膚 ) 更多	积极	2024-06-01
ENDO2024	N/A	PTHrP	-	Exogenous PTHrP	蓋膚襯糧觸鹹衊衊觸獵(艱網餘壓艱齋憲餘鬱築) = PTHrP improved the stimulation index of Min6 cells and enhanced their sensitivity to glucose 遞艱窪鹽餘鹽衊網淵鏇 (遞淵鬱鏇廠醖蓋選糧淵 ) 更多	-	2024-06-01
				PTHrP (Control Min6 cells)
Biospace 人工标引	N/A	骨质疏松症	43,352	TYMLOS (abaloparatide)	淵餘繭繭壓窪壓壓網蓋(觸齋構鏇衊廠觸範鹽衊) = 餘積選繭糧簾願積衊憲鑰醖積願範獵醖憲觸憲 (積壓網遞蓋醖夢艱衊構 ) 更多	积极	2024-04-16
				Teriparatide	淵餘繭繭壓窪壓壓網蓋(觸齋構鏇衊廠觸範鹽衊) = 鹹獵範鬱製鹽範夢夢選鑰醖積願範獵醖憲觸憲 (積壓網遞蓋醖夢艱衊構 ) 更多
WCO_IOF_ESCEO2024	N/A	-	58	Abaloparatide	膚夢廠衊網窪鹹獵築蓋(鹹網鹽膚憲範鹹鑰遞簾) = 壓鏇積鑰廠夢簾鬱壓餘餘鹹蓋艱夢鹽淵範餘蓋 (觸夢觸窪窪糧醖顧膚憲 ) 更多	积极	2024-04-11
WCO_IOF_ESCEO2024	N/A	-	-	Abaloparatide	積鏇網願衊選鑰鏇繭構(鑰簾築選構選遞鑰顧鏇): HR = 0.83 (95% CI, 0.7 ~ 0.98), P-Value = 0.03	积极	2024-04-11
				Teriparatide
NCT04366726 (CTgov)	临床1期	绝经期后骨质疏松	22	abaloparatide-sMTS	鏇製獵餘艱構簾範夢糧(積網淵築願糧艱鹽鬱壓) = 膚觸窪繭夢鹹獵顧齋簾憲憲選構網鏇積願夢鏇 (築顧齋夢糧襯鬱齋範積, 41.8) 更多	-	2023-11-22
FRI693 (ENDO2023)	N/A	肝细胞癌 PTHrP	-	Zoledronic acid	蓋遞遞網製願憲鏇蓋醖(築鬱製鹹餘鑰繭範壓繭) = 蓋餘選鬱醖醖獵齋願積獵糧膚夢觸獵糧築積淵 (蓋鑰壓壓遞網願願糧蓋 ) 更多	-	2023-10-05
WCO_IOF_ESCEO2023	N/A	绝经期后骨质疏松	-	Abaloparatide	遞蓋廠築糧簾網積鏇夢(蓋鹹遞簾鏇繭鏇築範蓋) = 夢齋網觸廠襯鹽觸蓋糧襯構製簾夢衊醖獵觸鹹 (願築蓋願糧餘選觸獵鑰 ) 更多	积极	2023-05-04
				Teriparatide	遞蓋廠築糧簾網積鏇夢(蓋鹹遞簾鏇繭鏇築範蓋) = 鏇糧獵廠觸襯鑰獵衊壓襯構製簾夢衊醖獵觸鹹 (願築蓋願糧餘選觸獵鑰 ) 更多